COLLEGIUM PHARMACEUTICAL, INC (COLL) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
COLL currently has 32.1M outstanding shares. with limited dilution risk as only 1.86M additional shares (5.8%) are authorized for issuance. The company has minimally diluted shareholders by 2.64% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 32.1M shares outstanding |
32M | 1.9M |
| Nov 06, 2025 |
10-Q filing | 31.6M shares outstanding |
32M | 2.4M |
| Aug 07, 2025 |
10-Q filing | 31.8M shares outstanding |
32M | 2.1M |
| May 12, 2025 |
8-K filing: Collegium Pharmaceutical, Inc. executed an accelerated share repurchase agreement with Jefferies LLC to repurchase $25 million of the Company's common stock, with an initial delivery of 692,281 shares based on the $28.89 closing stock price on May 9, 2025. ($25.0M proceeds) |
32M | 1.8M |
| May 08, 2025 |
10-Q filing | 31.8M shares outstanding |
32M | 2.2M |
| Feb 27, 2025 |
10-K filing | 32.3M shares outstanding |
32M | 1.7M |
| Nov 07, 2024 |
10-Q filing | 32.3M shares outstanding |
32M | 1.7M |
| Aug 08, 2024 |
10-Q filing | 32.4M shares outstanding |
32M | 1.5M |
| May 13, 2024 |
8-K filing: Collegium Pharmaceutical, Inc. executed an accelerated share repurchase agreement with Jefferies LLC to repurchase $35 million of the Company's common stock, with an initial delivery of 888,889 shares based on a $31.50 closing stock price. ($35.0M proceeds) |
33M | 1.2M |
| May 09, 2024 |
10-Q filing | 32.3M shares outstanding |
32M | 1.6M |
| Feb 22, 2024 |
10-K filing | 33.7M shares outstanding |
34M | 200K |
| Nov 09, 2023 |
8-K filing: Collegium Pharmaceutical, Inc. executed an accelerated share repurchase agreement with Jefferies LLC to repurchase $25 million of the Company's common stock, with an initial delivery of approximately 865,426 shares based on the $23.11 closing stock price on November 8, 2023. ($25.0M proceeds) |
33M | 850K |
| Nov 07, 2023 |
10-Q filing | 33.7M shares outstanding |
34M | 200K |
| Aug 07, 2023 |
8-K filing: Collegium Pharmaceutical, Inc. announced the execution of an accelerated share repurchase agreement with Jefferies LLC to repurchase $50 million of the Company's common stock, with an initial delivery of approximately 1.7 million shares. ($50.0M proceeds) |
35M | 0 |
| Aug 03, 2023 |
10-Q filing | 34.6M shares outstanding |
35M | 0 |
| May 04, 2023 |
10-Q filing | 34.3M shares outstanding |
34M | 0 |
| Feb 23, 2023 |
10-K filing | 33.8M shares outstanding |
34M | 120K |
| Feb 13, 2023 |
8-K filing: Collegium Pharmaceutical, Inc. issued $241,500,000 principal amount of 2.875% Convertible Senior Notes due 2029, with an option for initial purchasers to buy an additional $31,500,000, which was fully exercised. |
34M | 0 |
| Nov 03, 2022 |
10-Q filing | 34.1M shares outstanding |
34M | 0 |
| Aug 04, 2022 |
10-Q filing | 34.0M shares outstanding |
34M | 0 |
| May 10, 2022 |
10-Q filing | 33.7M shares outstanding |
34M | 270K |
| Feb 24, 2022 |
10-K filing | 34.9M shares outstanding |
35M | 0 |
| Nov 04, 2021 |
10-Q filing | 35.4M shares outstanding |
35M | 0 |
| Aug 05, 2021 |
10-Q filing | 35.3M shares outstanding |
35M | 0 |
| May 06, 2021 |
10-Q filing | 35.0M shares outstanding |
35M | 0 |
| Feb 25, 2021 |
10-K filing | 34.4M shares outstanding |
34M | 0 |
| Nov 05, 2020 |
10-Q filing | 34.5M shares outstanding |
35M | 0 |
| Aug 05, 2020 |
10-Q filing | 34.4M shares outstanding |
34M | 0 |
| May 07, 2020 |
10-Q filing | 34.1M shares outstanding |
34M | 0 |
| Mar 16, 2020 |
S-3 filing: This prospectus relates to the offer and sale by Assertio Therapeutics, Inc. of up to 1,041,667 shares of Collegium Pharmaceutical, Inc.'s common stock, par value $0.001 per share, issuable upon exercise of a warrant issued to Assertio Therapeutics, Inc. on November 8, 2018. |
33M | 1M |
| Feb 27, 2020 |
10-K filing | 32.9M shares outstanding |
33M | 0 |